Ticker > Company >

Kwality Pharma share price

Kwality Pharmaceuticals Ltd.

  59.69 K   363   16 NSE: KPL BSE: 539997 SECTOR: Pharmaceuticals & Drugs

3451.00
-78.15 (-2.21%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 3536.45

Today's Low

₹ 3440

52 Week High

₹ 3725.45

52 Week Low

₹ 828.8

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3580.83 Cr.

Enterprise Value

3707.75 Cr.

No. of Shares

1.04 Cr.

P/E

44.19

P/B

10

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  345.21

CASH

3.54 Cr.

DEBT

130.46 Cr.

Promoter Holding

54.86 %

EPS (TTM)

₹  78.1

Sales Growth

35.89%

ROE

22.54 %

ROCE

23.9%

Profit Growth

68.83 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year35.89%
3 Year26.08%
5 Year13.98%

Profit Growth

1 Year68.83%
3 Year51.24%
5 Year34.3%

ROE%

1 Year22.54%
3 Year16.69%
5 Year31.77%

ROCE %

1 Year23.9%
3 Year18.61%
5 Year33.06%

Debt/Equity

0.3923

Price to Cash Flow

210.64

Interest Cover Ratio

9.1577

CFO/PAT (5 Yr. Avg.)

0.792481299097717

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 54.86 0.00
Mar 2026 54.87 0.00
Dec 2025 54.83 0.00
Sep 2025 54.83 0.00
Jun 2025 54.83 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 51.2372704310774% for the Past 3 years.
  • The company has shown a good revenue growth of 26.0812256788119% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 9.1577.
  • The Company has been maintaining an effective average operating margins of 25.7652345292981% in the last 5 years.
  • Company’s PEG ratio is 0.641963423656377.
  • The company has an efficient Cash Conversion Cycle of 57.0823 days.
  • The company has a high promoter holding of 54.86%.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 111.48 111.31 123.45 156.82 162.35
Total Expenditure 87.29 85.96 93.49 118.08 121.33
Operating Profit 24.19 25.35 29.95 38.74 41.02
Other Income 0.38 0.9 0.53 1.06 0.62
Interest 2.76 2.84 2.48 2.89 2.66
Depreciation 4.76 4.96 4.82 5.26 4.99
Exceptional Items 0 0 -0.83 0 0
Profit Before Tax 17.04 18.45 22.35 31.65 33.99
Tax 5.11 4.34 6.35 6.36 8.37
Profit After Tax 11.93 14.12 16.01 25.29 25.63
Adjusted EPS (Rs) 11.5 13.6 15.43 24.37 24.7

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 456.13 250.99 307.17 370.2 503.06
Total Expenditure 284.41 190.12 240.54 289.75 384.83
Operating Profit 171.72 60.88 66.63 80.44 118.23
Other Income 3.51 2.94 1.83 1.92 2.86
Interest 2.92 6.61 10.39 9.88 10.97
Depreciation 10.64 14.92 19.51 18.26 19.79
Exceptional Items 0 -16.53 -7.1 0 -0.83
Profit Before Tax 161.67 25.76 31.47 54.23 89.49
Tax 41.63 6.29 7.48 14.34 22.15
Net Profit 120.05 19.47 23.98 39.89 67.35
Adjusted EPS (Rs.) 115.69 18.76 23.11 38.44 64.9

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 10.38 10.38 10.38 10.38 10.38
Total Reserves 172.18 191.65 215.57 255.47 323
Borrowings 20.29 27.3 19.56 15.12 29.4
Other N/C liabilities 1.03 1.31 0.19 -1.36 4.87
Current liabilities 138.8 125.94 151.85 169.51 225.52
Total Liabilities 342.68 356.58 397.55 449.11 593.16
Assets
Net Block 90.77 119.57 138.18 144.47 154.36
Capital WIP 12.15 14.29 0 0 17.01
Intangible WIP 0 0 0 0 0
Investments 3.55 3.55 3.55 3.55 3.55
Loans & Advances 8.11 10.71 12.44 16.19 11.45
Other N/C Assets 0.78 0.93 0 0 0
Current Assets 227.32 207.52 243.38 284.9 406.79
Total Assets 342.68 356.58 397.55 449.11 593.16
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 161.67 25.76 31.47 54.23 89.49
Adjustment 13.51 20.91 36.61 27.97 31.25
Changes in Assets & Liabilities -74.59 1.67 -23.43 -13.64 -82.98
Tax Paid -41.35 -6.16 -1.3 -15.79 -20.77
Operating Cash Flow 59.24 42.19 43.35 52.77 17
Investing Cash Flow -62.98 -48.44 -26.4 -28.13 -34.91
Financing Cash Flow 5.66 0.99 -17.4 -14.44 7.04
Net Cash Flow 1.93 -5.26 -0.45 10.2 -10.87

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 54.83 54.83 54.83 54.87 54.86
aditya arora 11.95 11.95 11.95 11.96 11.96
ajay arora 13.59 13.59 13.59 13.60 13.60
anju arora 1.31 1.31 1.31 1.31 1.31
geeta arora 1.07 1.07 1.07 1.07 1.07
jugal kishore huf 0.89 0.89 0.89 0.89 0.89
ramesh arora 26.01 26.01 26.01 26.03 26.03
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 45.17 45.17 45.17 45.13 45.14
ark global emerging compa... - - - 2.11 2.11
deepak bansal 10.63 10.63 10.63 9.24 8.39
dheeraj kumar lohia 1.89 1.88 1.88 1.86 1.66
investor education and pr... - - 0.97 0.97 0.97
jani bhasha shaik 1.45 1.45 1.45 1.45 1.45
kadayam ramnathan bharat 1.98 1.98 1.98 1.98 1.98
manohar devabhaktuni 4.98 4.98 4.98 4.98 4.98
onkar singh 1.09 1.09 1.09 1.09 1.09
investor education and pr... 0.97 0.97 - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2025
Annual Report 2024
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY27
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY22
Presentation FY2024

Company News

Kwality Pharma - Quaterly Results 11 Aug, 12:00 AM Kwality Pharmaceuticals informs about compliances-certificate 13 Jul, 4:55 PM Kwality Pharma - Quaterly Results 20 May, 12:00 AM Kwality Pharmaceuticals informs about disclosure 10 Mar, 5:13 PM Kwality Pharmaceuticals informs about investors meeting 5 Mar, 5:34 PM Kwality Pharmaceuticals informs about press release 20 Feb, 2:46 PM Kwality Pharma - Quaterly Results 13 Feb, 12:00 AM Kwality Pharmaceuticals informs about board meeting 2 Feb, 5:27 PM Kwality Pharmaceuticals informs about confirmation certificate 14 Jan, 12:11 PM Kwality Pharmaceuticals informs about successful completion of the EU-GMP audit 6 Nov, 5:00 PM Kwality Pharmaceuticals gets registration for Bleomycin in Mexico 18 Aug, 2:10 PM Kwality Pharma - Quaterly Results 11 Aug, 2:22 PM Kwality Pharma - Quaterly Results 11 Aug, 2:22 PM Kwality Pharma - Quaterly Results 11 Aug, 2:22 PM Kwality Pharmaceuticals informs about confirmation certificate 14 Jul, 5:29 PM Kwality Pharma - Quaterly Results 19 May, 5:43 PM Kwality Pharma - Quaterly Results 19 May, 5:43 PM Kwality Pharma - Quaterly Results 19 May, 5:43 PM Kwality Pharmaceuticals informs about disclosure 7 May, 12:19 PM Kwality Pharma - Quaterly Results 31 Jan, 6:54 PM Kwality Pharma - Quaterly Results 31 Jan, 6:54 PM Kwality Pharmaceuticals informs about disclosure 21 Jan, 12:12 PM Kwality Pharmaceuticals gets nod to start pre-clinical toxicity studies for Erythropoietin product 2 Jan, 3:29 PM Kwality Pharmaceuticals gets product approval for Tamoxifen tablet in South Africa 24 Dec, 3:59 PM Kwality Pharmaceuticals informs about disclosure 26 Nov, 5:02 PM Kwality Pharmaceuticals informs about updates 26 Nov, 4:46 PM Kwality Pharmaceutical gets approval for manufacturing and sale of PEGylated-Asparaginase 26 Nov, 3:59 PM Kwality Pharmaceuticals gets nod for Leuprorelin Acetate 11.25 mg vial powder & solvent for injectable suspension 6 Nov, 5:44 PM Kwality Pharma - Quaterly Results 30 Oct, 6:31 PM Kwality Pharma - Quaterly Results 30 Oct, 6:31 PM Kwality Pharma - Quaterly Results 10 Aug, 6:42 PM Kwality Pharma - Quaterly Results 10 Aug, 6:42 PM Kwality Pharma - Quaterly Results 10 Aug, 6:42 PM Kwality Pharma - Quaterly Results 23 May, 8:20 PM Kwality Pharma - Quaterly Results 23 May, 8:20 PM Kwality Pharma - Quaterly Results 6 Feb, 7:40 PM Kwality Pharma - Quaterly Results 6 Feb, 7:40 PM Kwality Pharmaceuticals informs about confirmation certificate 15 Jan, 12:19 PM Kwality Pharma - Quaterly Results 4 Nov, 8:48 PM Kwality Pharma - Quaterly Results 10 Aug, 7:21 PM Kwality Pharma - Quaterly Results 10 Aug, 7:21 PM Kwality Pharmaceuticals informs about disclosure 1 Jul, 2:20 PM Kwality Pharmaceuticals informs about disclosure 9 Jun, 12:15 PM Kwality Pharma - Quaterly Results 27 May, 8:12 PM Kwality Pharmaceuticals gets EU GMP approval for Himachal Pradesh facility 24 Apr, 5:58 PM Kwality Pharmaceuticals informs about change in directorate 17 Mar, 2:38 PM Kwality Pharma - Quaterly Results 14 Feb, 8:30 PM Kwality Pharmaceuticals informs about disclosure 21 Jan, 3:45 PM Kwality Pharmaceuticals informs about disclosure 21 Jan, 2:56 PM Kwality Pharmaceuticals informs about confirmation certificate 10 Jan, 11:51 AM

Kwality Pharma Stock Price Analysis and Quick Research Report. Is Kwality Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Kwality Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Kwality Pharma has a PE ratio of 45.2323912372645 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Kwality Pharma has ROA of 12.9231% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Kwality Pharma has a Current ratio of 1.8038.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Kwality Pharma has a ROE of 22.5384%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Kwality Pharma has a Debt to Equity ratio of 0.3923 which means that the company has low proportion of debt in its capital.

  • Sales growth: Kwality Pharma has reported revenue growth of 35.8895% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Kwality Pharma for the current financial year is 23.5018603189408%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Kwality Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Kwality Pharma is Rs 78.0989. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Kwality Pharma in Ticker for free. Also, one can get the intrinsic value of Kwality Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Kwality Pharma FAQs

Q1. What is Kwality Pharma share price today?
Ans: The current share price of Kwality Pharma is Rs 3532.6.

Q2. What is the market capitalisation of Kwality Pharma?
Ans: Kwality Pharma has a market capitalisation of Rs 3665.49570548 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Kwality Pharma?
Ans: The PE ratio of Kwality Pharma is 45.2323912372645 and the P/B ratio of Kwality Pharma is 10.2331439615586, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Kwality Pharma share?
Ans: The 52-week high share price of Kwality Pharma is Rs 3744, and the 52-week low share price of Kwality Pharma is Rs 1561.

Q5. Does Kwality Pharma pay dividends?
Ans: Currently, Kwality Pharma does not pay dividends. Dividend yield of Kwality Pharma is around 0%.

Q6. What are the face value and book value of Kwality Pharma shares?
Ans: The face value of Kwality Pharma shares is Rs 10, while the book value per share of Kwality Pharma is around Rs 345.2116. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Kwality Pharma?
Ans: Kwality Pharma has a total debt of Rs 130.4606 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Kwality Pharma?
Ans: The ROE of Kwality Pharma is 22.5384% and ROCE of Kwality Pharma is 23.9049%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Kwality Pharma a good buy for the long term?
Ans: The Kwality Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Kwality Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Kwality Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Kwality Pharma’s financials?
Ans: You can review Kwality Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Kwality Pharma
X